Literature DB >> 30060197

Enteric fever among children: 50 cases in a French tertiary care centre.

Virginie Pommelet1, Patricia Mariani2,3, Romain Basmaci1,4, Mathieu Tourdjman5, Laurence Morin6, Jean Gaschignard1, Agathe de Lauzanne1, Chloé Lemaitre1, Stéphane Bonacorsi2,3, Albert Faye1,4.   

Abstract

Background: Enteric fever in France is primarily travel-associated. Characteristics of paediatric cases are scarce and information from field studies in endemic countries might not be generalizable to non-endemic countries.
Methods: In this retrospective study, we reviewed all cases of typhoid and paratyphoid fever treated in a French paediatric tertiary care centre from 1993 to 2015.
Results: Fifty cases of enteric fever due to Salmonella enterica serovar Typhi (n = 44) and Paratyphi (n = 6) were identified. Sixty-one percent of the children had travelled to Africa and 34% to the Indian subcontinent. Among travel-associated cases, 85% were visiting friends and relatives (VFR). Ninety-six percent had high fever associated with gastrointestinal symptoms. Anaemia (66%), elevated C-reactive protein (80%), transaminitis (87%) and mild hyponatremia (50%) were the main biological findings. Blood cultures were positive in 90% of cases. Twelve strains (24%) were resistant at least to one antibiotic, and all of them had been isolated since 2003, increasing the resistance rate during this last period to 43% (12/28). Ceftriaxone was administered to 71 patients for a median duration of 6 days (interquartile range (IQR): 4-8). The median time to apyrexia after the onset of treatment was 4 days (IQR: 2-5 days). Complications occurred in nine children with five (10%) presenting neurologic disorders. All 50 patients recovered.
Conclusion: In France, paediatric enteric fever is mainly a travel-associated disease and occurs in patients returning from a prolonged stay in an endemic area. Children VFR are at high risk and should be a priority target group for pre-travel preventive measures. The increase in antibiotic resistance reflects the situation in endemic countries and is a major concern.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30060197     DOI: 10.1093/jtm/tay059

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  5 in total

1.  Prevention of enteric fever in travellers with typhoid conjugate vaccines.

Authors:  Carl Britto; Celina Jin; Katherine Theiss-Nyland; Andrew J Pollard
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

2.  Epidemiological and Clinical Characteristics of International Travelers with Enteric Fever and Antibiotic Resistance Profiles of Their Isolates: a GeoSentinel Analysis.

Authors:  Stefan H F Hagmann; Kristina M Angelo; Ralph Huits; Katherine Plewes; Gilles Eperon; Martin P Grobusch; Anne McCarthy; Michael Libman; Eric Caumes; Daniel T Leung; Hilmir Asgeirsson; Mogens Jensenius; Eli Schwartz; Adrian Sánchez-Montalvá; Paul Kelly; Prativa Pandey; Karin Leder; Daniel L Bourque; Yukihiro Yoshimura; Frank P Mockenhaupt; Perry J J van Genderen; Silvia Odolini; Patricia Schlagenhauf; Bradley A Connor; Davidson H Hamer
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 3.  Travel-Related Antimicrobial Resistance: A Systematic Review.

Authors:  Hamid Bokhary; Krisna N A Pangesti; Harunor Rashid; Moataz Abd El Ghany; Grant A Hill-Cawthorne
Journal:  Trop Med Infect Dis       Date:  2021-01-16

Review 4.  Travel-Related Typhoid Fever: Narrative Review of the Scientific Literature.

Authors:  Narcisa Muresu; Giovanni Sotgiu; Bianca Maria Are; Andrea Cossu; Clementina Cocuzza; Marianna Martinelli; Sergio Babudieri; Riccardo Are; Marco Dettori; Antonio Azara; Laura Saderi; Andrea Piana
Journal:  Int J Environ Res Public Health       Date:  2020-01-18       Impact factor: 3.390

5.  Antimicrobial Resistance in the Asia Pacific region: a meeting report.

Authors:  Esabelle Lo Yan Yam; Li Yang Hsu; Eric Peng-Huat Yap; Tsin Wen Yeo; Vernon Lee; Joergen Schlundt; May O Lwin; Direk Limmathurotsakul; Mark Jit; Peter Dedon; Paul Turner; Annelies Wilder-Smith
Journal:  Antimicrob Resist Infect Control       Date:  2019-12-18       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.